Literature DB >> 15709132

Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.

Elisabetta Pagani1, Maria A Rocca, Antonio Gallo, Marco Rovaris, Vittorio Martinelli, Giancarlo Comi, Massimo Filippi.   

Abstract

BACKGROUND AND
PURPOSE: Progressive brain atrophy is a well-known feature of multiple sclerosis (MS). We characterized the spatial evolution of atrophy in different MS phenotypes.
METHODS: Dual-echo and T1-weighted MR images were obtained in 70 patients with MS and 10 healthy control subjects at entry and after 15 months. Within-group changes in regional atrophy were assessed by applying Structural Image Evaluation Using Normalization of Atrophy software and statistical parametric mapping analysis. Reported differences are for P <.001.
RESULTS: During follow-up, patients with relapsing-remitting MS (RRMS) differences significant atrophy around the ventricular system; pericerebellar spaces; cerebellar tentorium; putamen; corpus callosum; cingulate sulcus; hippocampus; parieto-occipital fissure; lateral fissure; and frontal, parietal, temporal, and occipital cortex. Patients with secondary progressive MS developed significant atrophy of the cingulate sulcus; pulvinar; caudate nucleus; anterior orbital gyrus; mammillary body; fourth ventricle; and regions of frontal, parietal, temporal, and occipital cortex. Patients with primary progressive MS developed significant atrophy of the bilateral central sulcus; caudate nucleus; prepontine and quadrigeminal cisterns; lateral ventricle; and regions of frontal, parietal, temporal, and occipital cortex. In all phenotypes, the development of atrophy in some regions was significantly correlated with the accumulation of T2- and T1-visible lesions and clinical disability (r = -0.57 to -0.86).
CONCLUSION: In MS, brain atrophy develops involving different structures in the different phenotypes. While ventricular enlargement is predominant in RRMS, cortical atrophy seems to be more important in the progressive forms. Measures of regional brain atrophy were significantly correlated with disability, suggesting that this approach is promising for bridging the gap between clinical and MR imaging findings in MS.

Entities:  

Mesh:

Year:  2005        PMID: 15709132      PMCID: PMC7974082     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  46 in total

1.  Multisubject fMRI studies and conjunction analyses.

Authors:  K J Friston; A P Holmes; C J Price; C Büchel; K J Worsley
Journal:  Neuroimage       Date:  1999-10       Impact factor: 6.556

Review 2.  Voxel-based morphometry--the methods.

Authors:  J Ashburner; K J Friston
Journal:  Neuroimage       Date:  2000-06       Impact factor: 6.556

3.  Thalamic neurodegeneration in multiple sclerosis.

Authors:  Alberto Cifelli; Marzena Arridge; Peter Jezzard; Margaret M Esiri; Jacqueline Palace; Paul M Matthews
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

4.  Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis.

Authors:  Ralph H B Benedict; Rohit Bakshi; Jack H Simon; Roger Priore; Colleen Miller; Frederick Munschauer
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

5.  Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings.

Authors:  R Bakshi; R H Benedict; R A Bermel; L Jacobs
Journal:  J Neuroimaging       Date:  2001-04       Impact factor: 2.486

6.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

Authors:  M Filippi; M Bozzali; M Rovaris; O Gonen; C Kesavadas; A Ghezzi; V Martinelli; R I Grossman; G Scotti; G Comi; A Falini
Journal:  Brain       Date:  2003-02       Impact factor: 13.501

Review 7.  Cognitive dysfunction in multiple sclerosis: a review of recent developments.

Authors:  Julie A Bobholz; Stephen M Rao
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

8.  Diagnostic criteria for primary progressive multiple sclerosis: a position paper.

Authors:  A J Thompson; X Montalban; F Barkhof; B Brochet; M Filippi; D H Miller; C H Polman; V L Stevenson; W I McDonald
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

9.  Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

Authors:  N De Stefano; P M Matthews; M Filippi; F Agosta; M De Luca; M L Bartolozzi; L Guidi; A Ghezzi; E Montanari; A Cifelli; A Federico; S M Smith
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

10.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; G J M Parker; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

View more
  46 in total

1.  Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development.

Authors:  Juha Martola; Leszek Stawiarz; Sten Fredrikson; Jan Hillert; Jakob Bergström; Olof Flodmark; Maria Kristoffersen Wiberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-21       Impact factor: 10.154

2.  Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis.

Authors:  Ruchika Shaurya Prakash; Erin M Snook; Robert W Motl; Arthur F Kramer
Journal:  Brain Res       Date:  2009-06-25       Impact factor: 3.252

3.  Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects.

Authors:  Kerstin Bendfeldt; Louis Hofstetter; Pascal Kuster; Stefan Traud; Nicole Mueller-Lenke; Yvonne Naegelin; Ludwig Kappos; Achim Gass; Thomas E Nichols; Frederik Barkhof; Hugo Vrenken; Stefan D Roosendaal; Jeroen J G Geurts; Ernst-Wilhelm Radue; Stefan J Borgwardt
Journal:  Hum Brain Mapp       Date:  2011-04-29       Impact factor: 5.038

4.  Reduced Global Efficiency and Random Network Features in Patients with Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment.

Authors:  R Hawkins; A S Shatil; L Lee; A Sengupta; L Zhang; S Morrow; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-20       Impact factor: 3.825

5.  Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.

Authors:  Martijn D Steenwijk; Marita Daams; Petra J W Pouwels; Lisanne J Balk; Prejaas K Tewarie; Jeroen J G Geurts; Frederik Barkhof; Hugo Vrenken
Journal:  Hum Brain Mapp       Date:  2015-01-27       Impact factor: 5.038

Review 6.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

Review 7.  Progressive multiple sclerosis and gray matter pathology: an MRI perspective.

Authors:  Matilde Inglese; Niels Oesingmann; Patrizia Casaccia; Lazar Fleysher
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

8.  A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images.

Authors:  Juha Martola; Jakob Bergström; Sten Fredrikson; Leszek Stawiarz; Jan Hillert; Yi Zhang; Olof Flodmark; Anders Lilja; Anders Ekbom; Peter Aspelin; Maria Kristoffersen Wiberg
Journal:  Neuroradiology       Date:  2009-09-23       Impact factor: 2.804

9.  A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis.

Authors:  A Prinster; M Quarantelli; R Lanzillo; G Orefice; G Vacca; B Carotenuto; B Alfano; A Brunetti; V Brescia Morra; M Salvatore
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

Review 10.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.